3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Gastrointestinal Neoplasms
1
Clonal Cytopenia of Undetermined Significance
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
25
Cisplatin
23
Carboplatin
18
Magnetic Resonance Spectroscopy
16
Paclitaxel
15
Specimen Handling
14
Pemetrexed
11
durvalumab
9
Radiotherapy, Intensity-Modulated
8
Platinum
8
1,2-diaminocyclohexaneplatinum II citrate
8
Nivolumab
7
Radiation
6
Docetaxel
6
Cetuximab
6
Biopsy
6
osimertinib
5
cemiplimab
5
Taxes
5
Radiotherapy
5
Ipilimumab
5
Cyclophosphamide
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
poly ICLC
4
cabozantinib
4
atezolizumab
4
Oxaliplatin
4
Gemcitabine
4
Fluorouracil
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma
×
canakinumab
×
1 year
×
Clear all
No trials found.